Empagenta Tablets 25/5 mg (Empagliflozin, Linagliptin)
Empagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
MFDS item code 202503083 · Approved 2025.11.26
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. The combination of empagliflozin and linagliptin effectively manages blood sugar levels, which can improve symptoms of diabetes. This helps stabilize blood sugar levels and aids in the prevention of complications.
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. For patients who tolerate empagliflozin 10 mg/linagliptin 5 mg but require additional glycemic control, the dose of this medicine may be increased to 25/5 mg once daily. Patients switching from combination therapy with empagliflozin and linagliptin to this medicine should receive the same doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This medicine is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment is necessary based on age. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This medication consists of two active ingredients, empagliflozin and linagliptin, and is mainly used for the treatment of type 2 diabetes. This medication should not be administered to certain patients. For example, individuals who are allergic to empagliflozin, linagliptin, or any other components of this medication, patients with type 1 diabetes, diabetic ketoacidosis, patients undergoing renal dialysis, and individuals with lactose intolerance or related genetic issues should not take this medication. Patients with impaired kidney function may experience altered effectiveness from this medication, so regular monitoring of kidney function should be performed before and during treatment. Additionally, patients with heart failure should use this medication with caution and it is not recommended for patients with severe heart failure. This medication may cause rare side effects such as pancreatitis or bullous pemphigoid, so if severe abdominal pain or skin blisters occur during use, consult a doctor immediately. The most common side effect is urinary tract infection, and other potential effects include hypoglycemia, thirst, cough, constipation, itching, and rash. Caution is especially necessary when taken in conjunction with insulin or sulfonylureas as the risk of hypoglycemia may increase. This medication can cause fluid loss or low blood pressure, so use it carefully in individuals with low blood pressure or in the elderly. Additionally, though rare, a severe infection known as Fournier's gangrene may occur, so if there is pain, fever, or swelling around the genital area, immediate medical treatment should be sought. Pregnant or breastfeeding women are advised not to use this medication and it is not safe or effective for children under 18 years old. In the event of an overdose, seek medical attention immediately and keep out of reach of children. Lastly, this medication may have a mild effect on driving or operating machinery, so caution is needed, especially when taken with other medications that have a risk of hypoglycemia.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is best to store the medication at room temperature, between 1 and 30 degrees Celsius, avoiding extremes of temperature.
Pale pink triangular film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Dongkoo Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.